Roivant Sciences (ROIV) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Roivant Sciences (ROIV) has outperformed United Therapeutics (UTHR) over the past year, gaining 113.4% versus a gain of 18.7%. Over five years, ROIV leads with a +468.3% price change compared with +184.8% for UTHR. Roivant Sciences is the larger company by market cap ($24.71 billion vs $22.85 billion), about 1.1 times the size, while United Therapeutics is growing revenue faster (+10.6% vs -71.6%).
United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus -3629.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ROIV | UTHR |
|---|---|---|
| Share price | $34.21 | $532.78 |
| Market cap | $24.71B | $22.85B |
| 1-day change | -1.55% | -2.24% |
| YTD return | +57.65% | +9.34% |
| 1-year return | +113.41% | +18.68% |
| 5-year return | +468.27% | +184.80% |
| P/E ratio (TTM) | — | 19.08 |
| Forward P/E | — | 17.04 |
| EPS (TTM) | $-0.53 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.26M | $3.18B |
| Revenue growth (YoY) | -71.57% | +10.61% |
| Net income (latest FY) | $-299.77M | $1.33B |
| Gross margin | — | 87.92% |
| Operating margin | -6235.69% | 46.89% |
| Net margin | -3629.19% | 41.94% |
| 52-week high | $42.50 | $609.35 |
| 52-week low | $15.90 | $409.07 |
| Distance from 52-week high | -19.51% | -12.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +40.54% | +21.93% |
| Average volume | 7.04M | 672.80K |
| Shares outstanding | 722.32M | 42.89M |
| Employees | 721 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ROIV has outperformed UTHR by 94.7 percentage points over the past year.
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus -3629.2 cents for Roivant Sciences.
- United Therapeutics grew revenue faster in its latest fiscal year (+10.61% vs -71.57%).
About Roivant Sciences
ROIV stock →Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 721 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
ROIV vs UTHR FAQ
Which is bigger, Roivant Sciences or United Therapeutics?
Roivant Sciences (ROIV) is larger, with a market capitalization of $24.71B compared with $22.85B for United Therapeutics (UTHR).
Which stock has performed better over the past year, ROIV or UTHR?
ROIV returned +113.41% over the past 12 months, compared with +18.68% for UTHR (price return, excluding dividends). Past performance does not predict future results.
Are Roivant Sciences and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.